Myelofibrosis Market Summary<\/p>\n
The total myelofibrosis treatment market size in the leading markets (the US, EU4, UK, and Japan) was USD 2.2 billion in 2024.
\n The United States accounts for the largest market size of\u00a0myelofibrosis, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan.
\n Based on DelveInsight’s assessment in 2024, the 7MM had approximately 56K patient pool (prevalent cases) of myelofibrosis.
\n Key\u00a0myelofibrosis companies, including PharmaEssentia, AOP Orphan Pharmaceuticals, Incyte, Karyopharm Therapeutics, Geron, Bristol Myers Squibb, Kartos Therapeutics, Novartis, Merck, Telios Pharma, Ryvu Therapeutics, Sumitomo Pharma, Syntara, Disc Medicine, Menarini Group, and others, are actively working on innovative myelofibrosis drugs.
\n Some of the key\u00a0myelofibrosis therapies in clinical trials include BESREMi (ropeginterferon alfa-2b-njft\/P-1101), INCB057643, XPOVIO (NEXPOVIO\/selinexor\/KPT-330), RYTELO (imetelstat), REBLOZYL (luspatercept\/ACE-536), Navtemadlin (KRT-232), Pelabresib (DAK539), Bomedemstat (IMG-7289\/MK-3543), TL-895, RVU120 ( SEL-120), TP-3654 (nuvisertib), SNT-5505 (PXS-5505), DISC-0974, ELZONRIS (tagraxofusp\/SL-401),\u00a0and others. These novel myelofibrosis therapies are anticipated to enter the myelofibrosis market in the forecast period and are expected to change the market.
\n By 2034, among all the therapies, the highest revenue is expected to be generated by\u00a0OJJAARA\/OMJJARA.<\/p>\n
Discover which myelofibrosis\u00a0therapies are expected to grab the largest market share @ Myelofibrosis Market Report<\/a><\/p>\n Key Factors Driving the Growth of the Myelofibrosis Market\u00a0<\/p>\n Novel Therapies Drive Myelofibrosis Treatment Advancements<\/p>\n Currently, four JAK inhibitors have been approved by the US FDA for the treatment of myelofibrosis, including JAKAFI (ruxolitinib), INREBIC (fedratinib), VONJO (pacritinib), and OJJAARA (momelotinib). No drug therapy can cure myelofibrosis. As myelofibrosis primarily affects older adults, stem cell transplantation is not a treatment option for most myelofibrosis patients. The launch of another JAK inhibitor, BESREMi, will further change the dynamics of the myelofibrosis market.<\/p>\n Rich clinical pipeline and emerging non-JAK approaches driving the myelofibrosis landscape<\/p>\n Beyond JAK inhibitors, active clinical development includes BET inhibitors (Incyte’s INCB057643; Novartis’ Pelabresib), XPO1 inhibitor (Karyopharm Therapeutics’ XPOVIO), Telomerase inhibitor (Geron’s RYTELO), MDM2 protein inhibitor (Kartos Therapeutics’ Navtemadlin), Tyrosine kinase inhibitors (Telios Pharma’s TL-895), PIM1 kinase inhibitor (Sumitomo Pharma’s TP-3654), LOX inhibitor (Syntara’s SNT-5505), and others, raising market potential by promising new label expansions, second-line options, and higher-value therapies should any prove to be disease-modifying.<\/p>\n An aging population & increasing incidence with better survival<\/p>\n Myelofibrosis primarily affects older adults; population aging increases the absolute number of patients. As treatments improve symptoms and (in some cases) survival, prevalent patient pools grow, supporting longer-term market demand. In the US in 2024, the 70+ years of age group had the highest number of cases, accounting for approximately 60% of the total prevalent cases, while the \u226439 years of age group accounted for just ~2%.<\/p>\n Diagnostic & genomic testing improvements are driving myelofibrosis patient pool, leading to the growth of myelofibrosis market<\/p>\n Wider use of molecular profiling (JAK2, CALR, MPL, and others) enables earlier and more accurate MF diagnosis and better patient stratification for targeted therapies. This both expands the diagnosed population and helps match patients to appropriate, often higher-value, treatments.<\/p>\n Myelofibrosis Market Analysis<\/p>\n JAK inhibitors have become the cornerstone of treatment for patients with myelofibrosis, offering significant benefits such as spleen reduction, symptom relief, and improved quality of life, which can also extend survival in those with advanced disease. All approved JAK inhibitors primarily target JAK2, particularly the wild-type form, but they differ in their activity against other JAK family members.\u00a0<\/p>\n For instance, JAKAFI myelofibrosis inhibits both JAK1 and JAK2; INREBIC selectively inhibits JAK2 while sparing JAK1 and also affects FLT3 and other targets; VONJO myelofibrosis inhibits JAK2 while sparing JAK1 but additionally impacts FLT3, IRAK, and ACVR1; and OJJAARA, approved through a different pathway, targets JAK1\/JAK2 and ACVR1, mainly for myelofibrosis patients with anemia. These varying mechanisms lead to distinct patient outcomes.<\/p>\n JAKAFI myelofibrosis continues to see strong demand and is expected to grow further, maintaining its position as the standard of care in myelofibrosis. Myelofibrosis will remain the largest segment of JAKAFI’s patient population until polycythemia vera cases eventually increase. However, market growth may be limited due to patent expirations of key therapies, with JAKAFI patents set to expire in 2027 for Novartis and 2028 for Incyte, presenting potential opportunities for competitors. In response, Incyte is exploring combination trials with novel drugs to extend JAKAFI’s therapeutic lifespan.<\/p>\n Learn more about the treatment options for myelofibrosis @ Myelofibrosis Therapy<\/a><\/p>\n The myelofibrosis treatment landscape offers significant opportunities for innovation, focusing on several key areas:<\/p>\n Treating Lower-Risk Patients:\u00a0Developing safe and effective therapies for patients with lower-risk myelofibrosis, allowing for earlier and more favorable interventions. Myelofibrosis Competitive Landscape<\/p>\n The myelofibrosis clinical trial pipeline includes several drugs in mid- and late-stage development that are expected to enter the market during the forecast period. The emerging landscape offers a diverse range of therapeutic alternatives for treatment, including XPOVIO (Karyopharm Therapeutics), Elitracet (Takeda\/Keros Therapeutics), Navtemadlin (Kartos Therapeutics), Pelabresib (Novartis), INCB057643 (Incyte), Bomedemstat (Merck), and others, all of which are used in various lines of treatment. The expected launch of these therapies is expected to have a further positive impact on the market.<\/p>\n INCB57643 is an orally administered small molecule. Bromodomain and extra-terminal (BET) proteins act as epigenetic readers that control the expression of key oncoproteins implicated in the development of myelofibrosis and other hematologic malignancies, including B-lymphoma-2, nuclear factor kappa, and c-Myc. In a prior Phase I\/II clinical trial, the oral BET inhibitor INCB057643, tested both as a monotherapy and in combination with ruxolitinib, demonstrated favorable tolerability and promising clinical activity in patients with advanced cancers. In its Q2 2025 financial report, the company announced that the combination of INCB057643 with ruxolitinib and INCB57643 (a JAK1\/JAK2 and BET inhibitor) is currently being evaluated in a Phase II trial for myelofibrosis.<\/p>\n RYTELO (imetelstat)\u00a0is an investigational telomerase inhibitor that targets telomerase, selectively eliminating malignant stem and progenitor cells in the bone marrow, which drive diseases like myelodysplastic syndromes (MDS) and myelofibrosis. By blocking the proliferation of these malignant cells, imetelstat supports the recovery of healthy bone marrow and blood cell production and has shown disease-modifying effects and clinical benefits in Phase III trials for myelofibrosis. This mechanism sets imetelstat apart from other approved or investigational therapies for these blood cancers. In January 2025, Geron reported achieving 75% enrollment in the Phase III IMpactMF trial, which is comparing imetelstat to Best Available Therapy (BAT) in intermediate-2 or high-risk myelofibrosis patients who have relapsed or are refractory to JAK inhibitor treatment.<\/p>\n Elritercept is a late-stage investigational activin inhibitor aimed at treating anemia associated with hematologic malignancies, including MDS and myelofibrosis. It is currently undergoing Phase II evaluation in patients with myelofibrosis. In December 2024, Keros Therapeutics presented updated data from this ongoing Phase II trial at ASH 2024. Additionally, in December 2024, Takeda announced an exclusive licensing agreement with Keros to further develop, manufacture, and commercialize elritercept globally, excluding mainland China, Hong Kong, and Macau.<\/p>\n The anticipated launch of these emerging myelofibrosis therapies are poised to transform the myelofibrosis market landscape in the coming years. As these cutting-edge myelofibrosis therapies continue to mature and gain regulatory approval, they are expected to reshape the myelofibrosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n To know more about new myelofibrosis treatment, visit @ Myelofibrosis Treatment Market<\/a>\u00a0<\/p>\n Recent Developments in the Myelofibrosis Market<\/p>\n In July 2025, Incyte announced that the Phase I data in patients with myelofibrosis as monotherapy and in combination with ruxolitinib are anticipated in the second half of 2025. What is Myelofibrosis?<\/p>\n Myelofibrosis is a rare blood cancer marked by the accumulation of scar tissue, or ‘fibrosis’, in the bone marrow. This excess scar tissue prevents the bone marrow from producing enough healthy blood cells. It belongs to a group of blood cancers called ‘myeloproliferative neoplasms (MPNs)’, in which the blood cells produced by the bone marrow grow and function abnormally. When myelofibrosis arises independently, without being caused by another bone marrow disorder, it is referred to as primary myelofibrosis. In other cases, it can develop from another MPN, such as polycythemia vera or essential thrombocythemia. When this occurs, it is called secondary myelofibrosis, sometimes specifically termed post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.<\/p>\n Myelofibrosis Epidemiology Segmentation<\/p>\n The myelofibrosis\u00a0epidemiology section provides insights into the historical and current myelofibrosis patient pool and forecasted trends for the leading markets (the US, EU4, UK, and Japan). It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.<\/p>\n The myelofibrosis market report\u00a0proffers epidemiological analysis for the study period 2020\u20132034 in the leading markets (the US, EU4, UK, and Japan) segmented into:<\/p>\n Total Prevalent Cases of Myelofibrosis Download the report to understand which factors are driving myelofibrosis epidemiology trends @ Myelofibrosis Treatment Drugs<\/a><\/p>\n Myelofibrosis Market Report Metrics<\/p>\n Details<\/p>\n Study Period<\/p>\n 2020\u20132034<\/p>\n Myelofibrosis Market Report\u00a0Coverage<\/p>\n 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]<\/p>\n Myelofibrosis Market CAGR\u00a0<\/p>\n 9\u00a0%<\/p>\n Myelofibrosis Market Size in 2024<\/p>\n USD 2.2 Billion<\/p>\n Key Myelofibrosis Companies<\/p>\n PharmaEssentia, AOP Orphan Pharmaceuticals, Incyte, Karyopharm Therapeutics, Geron, Bristol Myers Squibb, Kartos Therapeutics, Novartis, Merck, Telios Pharma, Ryvu Therapeutics, Sumitomo Pharma, Syntara, Disc Medicine, Menarini Group, and others<\/p>\n Key Myelofibrosis Therapies<\/p>\n BESREMi (ropeginterferon alfa-2b-njft\/P-1101), INCB057643, XPOVIO (NEXPOVIO\/selinexor\/KPT-330), RYTELO (imetelstat), REBLOZYL (luspatercept\/ACE-536), Navtemadlin (KRT-232), Pelabresib (DAK539), Bomedemstat (IMG-7289\/MK-3543), TL-895, RVU120 ( SEL-120), TP-3654 (nuvisertib), SNT-5505 (PXS-5505), DISC-0974, ELZONRIS (tagraxofusp\/SL-401), and others<\/p>\n Scope of the Myelofibrosis\u00a0Market Report<\/p>\n Myelofibrosis Therapeutic Assessment: Myelofibrosis\u00a0current marketed and emerging therapies Discover more about myelofibrosis drugs\u00a0in development @ Myelofibrosis Clinical Trials<\/a><\/p>\n Table of Contents<\/p>\n 1<\/p>\n MYELOFIBROSIS MARKET KEY INSIGHTS<\/p>\n 2<\/p>\n MYELOFIBROSIS MARKET REPORT INTRODUCTION<\/p>\n 3<\/p>\n EXECUTIVE SUMMARY OF MYELOFIBROSIS<\/p>\n 4<\/p>\n MYELOFIBROSIS EPIDEMIOLOGY AND MARKET METHODOLOGY<\/p>\n 5<\/p>\n KEY EVENTS<\/p>\n 6<\/p>\n MYELOFIBROSIS MARKET OVERVIEW AT A GLANCE<\/p>\n 6.1<\/p>\n MARKET SHARE (%) DISTRIBUTION OF MYELOFIBROSIS BY THERAPIES IN 2024<\/p>\n 6.2<\/p>\n MARKET SHARE (%) DISTRIBUTION OF MYELOFIBROSIS BY THERAPIES IN 2034<\/p>\n 7<\/p>\n DISEASE BACKGROUND AND OVERVIEW<\/p>\n 7.1<\/p>\n INTRODUCTION<\/p>\n 7.2<\/p>\n MYELOFIBROSIS SUBTYPES<\/p>\n 7.3<\/p>\n MYELOFIBROSIS SIGNS AND SYMPTOMS<\/p>\n 7.4<\/p>\n MYELOFIBROSIS CAUSES<\/p>\n 7.5<\/p>\n MYELOFIBROSIS PATHOGENESIS<\/p>\n 7.6<\/p>\n MYELOFIBROSIS PROGNOSIS<\/p>\n 7.7<\/p>\n MYELOFIBROSIS RISK FACTOR<\/p>\n 7.8<\/p>\n MYELOFIBROSIS DIAGNOSIS<\/p>\n 8<\/p>\n MYELOFIBROSIS TREATMENT AND MANAGEMENT<\/p>\n 9<\/p>\n MYELOFIBROSIS GUIDELINES<\/p>\n 9.1<\/p>\n NCCN GUIDELINES<\/p>\n 9.2<\/p>\n NICE GUIDELINES<\/p>\n 9.3<\/p>\n ESMO GUIDELINES (POST PV AND POST ET)<\/p>\n 9.4<\/p>\n THE MANAGEMENT OF MYELOFIBROSIS: A BRITISH SOCIETY FOR HEMATOLOGY GUIDELINE<\/p>\n 10<\/p>\n MYELOFIBROSIS EPIDEMIOLOGY AND PATIENT POPULATION<\/p>\n 10.1<\/p>\n KEY FINDINGS<\/p>\n 10.2<\/p>\n ASSUMPTIONS AND RATIONALE<\/p>\n 10.3<\/p>\n TOTAL PREVALENT CASES OF MYELOFIBROSIS IN THE 7MM<\/p>\n 10.4<\/p>\n THE UNITED STATES<\/p>\n 10.4.1<\/p>\n Total Prevalent Cases of Myelofibrosis in the United States<\/p>\n 10.4.2<\/p>\n Type-specific Cases of Myelofibrosis in the United States<\/p>\n 10.4.3<\/p>\n Myelofibrosis Cases Based on Risk Stratification in the United States<\/p>\n 10.4.4<\/p>\n Age-specific Cases of Myelofibrosis in the United States<\/p>\n 10.4.5<\/p>\n Myelofibrosis Cases Based on Molecular Alterations in the United States<\/p>\n 10.5<\/p>\n EU4 AND THE UK<\/p>\n 10.6<\/p>\n JAPAN<\/p>\n 11<\/p>\n MYELOFIBROSIS PATIENT JOURNEY<\/p>\n 11.1<\/p>\n DESCRIPTION<\/p>\n 12<\/p>\n KEY ENDPOINTS IN MYELOFIBROSIS CLINICAL TRIALS<\/p>\n 13<\/p>\n MARKETED MYELOFIBROSIS DRUGS<\/p>\n 13.1<\/p>\n KEY COMPETITORS<\/p>\n 13.2<\/p>\n MYELOFIBROSIS JAKAFI\/JAKAVI (RUXOLITINIB): INCYTE\/NOVARTIS<\/p>\n 13.2.1<\/p>\n Product Description<\/p>\n 13.2.2<\/p>\n Regulatory Milestones<\/p>\n 13.2.3<\/p>\n Other Developmental Activities<\/p>\n 13.2.4<\/p>\n Clinical Development<\/p>\n 13.2.5<\/p>\n Safety and Efficacy<\/p>\n 13.2.6<\/p>\n Product Profile<\/p>\n 13.3<\/p>\n INREBIC (FEDRATINIB): BRISTOL MYERS SQUIBB<\/p>\n 13.4<\/p>\n VONJO MYELOFIBROSIS: SWEDISH ORPHAN BIOVITRUM\/CTI BIOPHARMA<\/p>\n 13.5<\/p>\n OJJAARA\/OMJJARA (MOMELOTINIB MYELOFIBROSIS): GSK\/SIERRA ONCOLOGY<\/p>\n 14<\/p>\n EMERGING MYELOFIBROSIS THERAPIES<\/p>\n 14.1<\/p>\n KEY COMPETITORS<\/p>\n 14.2<\/p>\n PELABRESIB: MORPHOSYS<\/p>\n 14.2.1<\/p>\n Product Description<\/p>\n 14.2.2<\/p>\n Other Developmental Activities<\/p>\n 14.2.3<\/p>\n Clinical Development<\/p>\n 14.2.4<\/p>\n Safety and Efficacy<\/p>\n 14.3<\/p>\n IMETELSTAT: GERON<\/p>\n 14.4<\/p>\n REBLOZYL (LUSPATERCEPT\/ACE-536): BRISTOL MYERS SQUIBB<\/p>\n 14.5<\/p>\n NAVTEMADLIN (KRT-232): KARTOS THERAPEUTICS<\/p>\n Further details in the report…<\/p>\n 15<\/p>\n MYELOFIBROSIS MARKET: 7 MAJOR MARKET ANALYSIS<\/p>\n 15.1<\/p>\n KEY FINDINGS<\/p>\n 15.2<\/p>\n MYELOFIBROSIS MARKET OUTLOOK<\/p>\n 15.3<\/p>\n CONJOINT ANALYSIS<\/p>\n 15.4<\/p>\n KEY MYELOFIBROSIS MARKET FORECAST ASSUMPTIONS<\/p>\n 15.5<\/p>\n TOTAL MARKET SIZE OF MYELOFIBROSIS IN THE 7MM<\/p>\n 15.6<\/p>\n UNITED STATES MYELOFIBROSIS MARKET SIZE<\/p>\n 15.6.1<\/p>\n Total Market Size of Myelofibrosis in the United States<\/p>\n 15.6.2<\/p>\n Market Size of Myelofibrosis by Therapies in the United States<\/p>\n 15.1<\/p>\n EU4 AND THE UK MYELOFIBROSIS MARKET SIZE<\/p>\n 15.2<\/p>\n JAPAN MYELOFIBROSIS MARKET SIZE<\/p>\n 16<\/p>\n MYELOFIBROSIS MARKET ACCESS AND REIMBURSEMENT<\/p>\n 16.1<\/p>\n UNITED STATES<\/p>\n 16.2<\/p>\n EU4 AND THE UK<\/p>\n 16.3<\/p>\n JAPAN<\/p>\n 16.4<\/p>\n MYELOFIBROSIS MARKET ACCESS AND REIMBURSEMENT<\/p>\n 16.4.1<\/p>\n United States<\/p>\n 16.4.2<\/p>\n NICE UK<\/p>\n 16.4.3<\/p>\n HAS France<\/p>\n 16.4.4<\/p>\n The Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM)<\/p>\n 16.4.5<\/p>\n IQWIG Germany<\/p>\n 16.4.6<\/p>\n The Federal Institute for Drugs and Medical Devices (BfArM)<\/p>\n 16.4.7<\/p>\n AIFA Italy<\/p>\n 16.4.8<\/p>\n MHLW Japan<\/p>\n 17<\/p>\n MYELOFIBROSIS MARKET SWOT ANALYSIS<\/p>\n 18<\/p>\n MYELOFIBROSIS MARKET UNMET NEEDS<\/p>\n 19<\/p>\n KOL VIEWS ON MYELOFIBROSIS\u00a0<\/p>\n 20<\/p>\n BIBLIOGRAPHY<\/p>\n 21<\/p>\n MYELOFIBROSIS MARKET REPORT METHODOLOGY<\/p>\n Related Reports<\/p>\n JAK Inhibitors Market<\/a><\/p>\n JAK Inhibitors Market Size, Target Population, Competitive Landscape, and Market Forecast \u2013 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key JAK inhibitors companies, including Pfizer, AbbVie, Galapagos, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, Gilead Sciences, Reistone Biopharma, Jiangsu Hengrui Medicine Co., MaxiNovel Pharmaceuticals, among others.<\/p>\n Myelofibrosis Clinical Trial Analysis<\/a><\/p>\n Myelofibrosis Pipeline Insight \u2013 2025\u00a0report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key\u00a0myelofibrosis companies, including Geron Corporation, Merck, Ryvu Therapeutics SA, Morphic Therapeutic, iOnctura, Pharmaxis, Nippon Shinyaku, Active Biotech, Incyte Corporation, Sumitomo Pharma America, Inc., Cellenkos, Disc Medicine, among others.<\/p>\n Polycythemia Vera Market<\/a><\/p>\n Polycythemia Vera Market Insights, Epidemiology, and Market Forecast \u2013 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key polycythemia vera\u00a0companies, including Incyte, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck (Imago BioSciences), Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience, Disc Medicine, GluBio Therapeutics, among others.<\/p>\n Multiple Myeloma Market<\/a><\/p>\n Multiple Myeloma Market Insights, Epidemiology, and Market Forecast \u2013 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple myeloma\u00a0companies, including Sanofi, Karyopharm Therapeutics, AbbVie, Takeda Pharmaceutical, Celgene, Bristol-Myers Squibb, RAPA Therapeutics, Pfizer, Array Biopharma, Cellectar Biosciences, BioLineRx, Celgene, Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie, Genentech (Roche), Janssen Biotech, Nanjing Legend Biotech, Merck Sharp & Dohme Corp., among others.<\/p>\n About\u00a0DelveInsight<\/p>\n DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve.<\/p>\n Connect with us on\u00a0LinkedIn<\/a> |\u00a0Facebook<\/a>\u00a0|\u00a0Twitter<\/a><\/p>\n Contact Us
\n Enhancing First-Line Treatments:\u00a0Improving existing first-line therapies for intermediate- to high-risk patients through novel drugs or combination strategies.
\n Managing Cytopenia:\u00a0Developing targeted therapies to address cytopenia, a significant unmet need in patient care.<\/p>\n
\n In June 2025, QIAGEN and Incyte announced a new global collaboration to develop a novel diagnostic panel to support Incyte’s extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), including Incyte’s monoclonal antibody INCA033989.
\n In January 2025, Karyopharm Therapeutics stated that it expects to report top-line results from the Phase III SENTRY trial in the second half of 2025, which could represent a potentially transformative opportunity to establish a new treatment paradigm in myelofibrosis.<\/p>\n
\n Type-specific Cases of Myelofibrosis
\n Myelofibrosis Cases Based on Risk Stratification
\n Age-specific Prevalent Cases of Myelofibrosis
\n Myelofibrosis Cases Based on Molecular Alterations\u00a0<\/p>\n
\n Myelofibrosis\u00a0Market Dynamics: Conjoint Analysis of Emerging Myelofibrosis\u00a0Drugs
\n Competitive Intelligence Analysis:\u00a0SWOT analysis and Market entry strategies
\n Myelofibrosis Market Unmet Needs, KOL’s views, Analyst’s views, Myelofibrosis Market Access and Reimbursement<\/p>\n
Shruti Thakur
[email\u00a0protected]<\/a>
+14699457679
www.delveinsight.com<\/a><\/p>\n
![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO64488&Transmission_Id=202509031731PR_NEWS_USPR_____IO64488&DateId=20250903\")
<\/p>\n